Alexion To Highlight Innovative Rare Disease Portfolio At Investor Day Meeting

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the Company will highlight significant progress in its early- and late-stage rare disease portfolio and provide updates on key aspects of its long-term growth strategy at an Investor Day meeting being held in New York. Alexion’s leadership team will discuss the corporate strategy to grow the Company’s complement franchise, build a leading metabolic franchise, advance its broad and robust rare disease pipeline, and expand innovation to new franchises.